Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaLaurie H Sehn, Alex F Herrera, Christopher R Flowers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and AzacitidineKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.The Lancet. Oncology|March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 studyJohn Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.Hematological Oncology|May 22, 2023
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world dataElif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, et al.Annals of Hematology|June 9, 2020
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experienceHuseyin Bekoz, Murat Ozbalak, Nuri Karadurmus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.Journal of Clinical Medicine|October 16, 2025
Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study GroupEmel Isleyen, Nurcan Alhan, Esra Terzi Demirsoy, et al.Pageof 6